Acadia Pharmaceuticals Inc., of San Diego, recorded net sales of Nuplazid (pimavanserin) of $90.1 million for the three months ended March 31, an increase of 43% as compared to $63 million reported in the same period last year. The company recorded a net loss of $88 million, or 57 cents per common share, compared to a net loss of $85.3 million, or 59 cents per common share, for the same period in 2019. The net losses for the three months ended March 31, 2020, and 2019 included $22.3 million and $19.9 million, respectively, of non-cash stock-based compensation expense. At March 31, Acadia’s cash, cash equivalents and investment securities totaled $651.4 million. The company's shares (NASDAQ:ACAD) closed Friday at $50.72, up $1.38.

Adamas Pharmaceuticals Inc., of Emeryville, Calif., reported that its sales of Gocovri (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinson's disease were $14.5 million for the first quarter of 2020, up 24% compared to $11.7 million in the same period in 2019. Its net loss was $16.6 million, or 59 cents per share, basic and diluted, for the first quarter of 2020, compared to a net loss of $29.7 million, or $1.08 per share, basic and diluted, for the first quarter of 2019. As of March 31, the company had $115.3 million of cash, cash equivalents and available-for-sale securities. The company's shares (NASDAQ:ADMS) closed Friday at $3, down 46 cents.

Biodelivery Sciences International Inc., of Raleigh, N.C., reported its net revenue for the first quarter increased by 94% vs. the prior year period to a record level of $38.3 million. The growth was driven by Belbuca (buprenorphine buccal film) sales of $33.5 million, an increase of 79% vs. the prior year period, and Symproic sales of $4.2 million, an increase of 54% compared to $2.7 million in the fourth quarter of 2019. GAAP net income was $5 million, or 5 cents per share, compared to GAAP net loss of $700,000, or 1 cent per share, for the fourth quarter of 2019 and GAAP net loss of $3.8 million, or 5 cents per share, in the first quarter of 2019. At the end of the period, the company’s cash and cash equivalents were approximately $70.6 million. The company's shares (NASDAQ:BDSI) closed Friday at $5.08, up 25 cents.

Coherus Biosciences Inc., of Redwood City, Calif., reported sales of its pegfilgrastim biosimilar, Udenyca (pegfilgrastim-cbqv), generated $116.2 million in the first quarter of 2020. Its gross profit margin was 94%, a 213% increase compared to the net product revenue of $37.1 million for the same period in 2019. Net income for the first quarter of 2020 was $35.6 million, or 48 cents per share on a diluted basis, compared to a net loss of $20 million, or 29 cents per share on a basic and diluted basis for the same period in 2019. Cash and cash equivalents were $193.3 million as of March 31, as compared to $177.7 million as of Dec. 31, 2019. The company's shares (NASDAQ:CHRS) closed Friday at $17.30, up 64 cents.

Collegium Pharmaceutical Inc., of Stoughton, Mass., achieved GAAP profitability in the first quarter with $500,000 in net income. Non-GAAP net income totaled $31.2 million. Prescriptions for Xtampza (oxycodone) grew 30% more than the same period last year, the company said. Xtampza ER net product revenues were $31.5 million for the first quarter, compared to $25.1 million for the same period in 2019, representing an increase of 25%. Net product revenues from the Nucynta (tapentadol) franchise were $45 million, compared to $49.4 million for the prior year quarter, representing a decrease of 9%. Collegium reported first-quarter net income of $500,000, or 1 cent per share, and ended the quarter with $116.2 million in cash and equivalents. Shares of Collegium (NASDAQ:COLL) closed May 8 at $21.47, up $1.14.

Dynavax Technologies Corp., of Emeryville, Calif., said first-quarter Heplisav-B net revenue reached $105 million, compared to $5.6 million in the same period last year. The firm has exceeded the minimum product revenue covenant in its term loan agreement of $30 million for the annual period ending June 30, 2020. Also, Dynavax has established multiple collaborations leveraging its vaccine adjuvant CpG 1018 in COVID-19 vaccine candidates across several technology platforms. The company’s net loss for the quarter was $12.6 million, or 15 cents per basic share and 25 cents per diluted share, compared to a net loss of $39.7 million, or 62 cents per basic and diluted share, for the first quarter of 2019. As of March 31, cash, equivalents and marketable securities totaled $129.5 million. Shares of Dynavax (NASDAQ:DVAX) closed May 8 at $4.25, down 29 cents.

Flexion Therapeutics Inc., of Burlington, Mass., reported Zilretta (triamcinolone acetonide extended-release injectable suspension) net sales of $20.1 million in the first quarter of 2020. The company said it is implementing broad cost-saving initiatives and provided guidance of total operating expenses in the range of $167 million to $177 million for this year. A phase II trial testing Zilretta in shoulder osteoarthritis and adhesive capsulitis has been discontinued, the company said, and a new trial will be started later. The company reported a net loss of $36.8 million for the quarter, compared to a net loss of $41.5 million for the same period in 2019. As of March 31, it had about $125.2 million in cash, cash equivalents and marketable securities. Shares of Flexion (NASDAQ:FLXN) fell $1.38 to close May 8 at $9.50.

Ocular Therapeutix Inc., of Bedford, Mass., said first-quarter Dextenza (dexamethasone ophthalmic insert) net product revenue reached $2.1 million, a 31% sequential increase compared with the fourth quarter of last year. The company said it believes there has been limited impact from COVID-19 to date on its ongoing clinical programs. Enrollment in the phase I trial with OTX-TIC in patients with primary open angle glaucoma or ocular hypertension has recently slowed but Ocular believes enrollment in cohort four will not be materially impacted and expects enrollment to pick up as ophthalmology practices begin to resume normal operations. The company reported a net loss of $21.5 million, or 41 cents per share on a basic and diluted basis, for the first quarter vs. a net loss of $17.1 million, or 41 cents per share on a basic and 45 cents per share on a diluted basis, for the same period in 2019. As of March 31, the company had $48.2 million in cash and cash equivalents. Shares of Ocular (NASDAQ:OCUL) closed May 8 at $5.97, down 67 cents.

Puma Biotechnology Inc., of Los Angeles, tallied net product revenue in the first quarter of 2020 totaling $48.6 million, compared to net product revenue of $45.6 million in the first quarter of 2019 from Nerlynx (neratinib), its first commercial product. The firm reported a GAAP net loss of $16.9 million, or 43 cents per share, compared to a net loss of $10.1 million, or 26 cents per share, for the first quarter of last year. Non-GAAP adjusted net loss was $8 million, or 20 cents per share, compared to $8.1 million, or 21 cents per basic share and 20 cents per diluted share, for the same period last year. Puma had about $83.4 million in cash and equivalents as of March 31. The company’s shares (NASDAQ:PUMA) closed May 8 at $11.10, up $1.22.

Radius Health Inc., of Waltham, Mass., reported Tymlos (abaloparatide) U.S. net sales of $48 million, with 61% year-over-year growth. Three phase III studies continue to advance amid slowdown in recruitment due to the COVID-19 pandemic. Anticipated data readouts remain on track for the second half of 2021, Radius said. Due to the anticipated impact of the pandemic, 2020 Tymlos U.S. net revenue guidance at midpoint was reduced by 10% to between $190 million and $220 million. The full-year cash burn is expected to be below $100 million. Radius reported a net loss of $37.7 million, or 81 cents per share, compared to a net loss of $42.8 million, or 94 cents per share, for the same period in 2019. As of March 31, the company had $138.5 million in cash, cash equivalents, restricted cash and marketable securities. Shares of Radius (NASDAQ:RDUS) closed May 8 at $14.57, down 45 cents.

Tetraphase Pharmaceuticals Inc., of Watertown, Mass., said it continues to see increased formulary uptake of Xerava (eravacycline), with a 99% success rate for all formulary reviews to date and $1.8 million in net sales for the first quarter of 2020, an increase of about 20% over the fourth quarter of 2019. Tetraphase’s sales force is focusing on bringing Xerava to targeted institutions, which are the highest users of antibiotics defined by days of therapy, noted the company, which has executed a definitive merger agreement with Acelrx Pharmaceuticals Inc., of Redwood City, Calif. As of March 31, Tetraphase had cash and cash equivalents of $26.1 million and 7.3 million shares outstanding. Shares of Tetraphase (NASDAQ:TTPH) closed May 8 at $2.02, down 40 cents.

No Comments